Under the banner of a joint research and development, Novo Nordisk and US-based biotech firm 2Seventy Bio will develop a drug candidate for genetic bleeding disorder hemophilia A, reports a press release from 2Seventy Bio.
The partnership builds upon an existing research collaboration between the two companies. Under the terms of the new deal, 2Seventy Bio receives an upfront payment of USD 5m, and the company is eligible for milestone payments of up to USD 35m as well as potential royalties from sales of the drug.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.